153 related articles for article (PubMed ID: 27698335)
1. Ibrutinib-induced pyoderma gangrenosum.
Sławińska M; Barańska-Rybak W; Sobjanek M; Wilkowska A; Mital A; Nowicki R
Pol Arch Med Wewn; 2016 Sep; 126(9):710-711. PubMed ID: 27698335
[No Abstract] [Full Text] [Related]
2. Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
Giovanni B; Ibatici A; Sola S; Brunasso AMG; Massone C
Am J Dermatopathol; 2020 Feb; 42(2):148-150. PubMed ID: 30839345
[No Abstract] [Full Text] [Related]
3. Imatinib induced pyoderma gangrenosum.
Pinato DJ; Sharma R
J Postgrad Med; 2013; 59(3):244-5. PubMed ID: 24029213
[No Abstract] [Full Text] [Related]
4. Large peristomal pyoderma gangrenosum successfully treated with cyclosporine and corticosteroids.
Martín de Hijas C; del-Río E; Gorospe MA; Vélez A; García del Pozo JA
J Am Acad Dermatol; 1993 Dec; 29(6):1034-5. PubMed ID: 7902367
[No Abstract] [Full Text] [Related]
5. Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
Harada K; Brooks JP; Lobo FM
Ann Allergy Asthma Immunol; 2018 Nov; 121(5):629-630.e1. PubMed ID: 30009879
[No Abstract] [Full Text] [Related]
6. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
[No Abstract] [Full Text] [Related]
7. [Pyoderma gangrenosum--an interdisciplinary diagnostic problem].
Torzecka JD; Kondras K; Dziankowska-Bartkowiak B; Waszczykowska E; Modzelewski B; Jurałowicz P; Kondras M
Pol Merkur Lekarski; 2008 Jan; 24(139):34-7. PubMed ID: 18634250
[TBL] [Abstract][Full Text] [Related]
8. Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Williams AM; Baran AM; Schaffer M; Bushart J; Rich L; Moore J; Barr PM; Zent CS
Am J Hematol; 2020 Jan; 95(1):E16-E18. PubMed ID: 31621100
[No Abstract] [Full Text] [Related]
9. Pyoderma gangrenosum associated with dulaglutide therapy.
Hamann CR; Chung C; Kaffenberger BH
Int J Dermatol; 2019 Oct; 58(10):1202-1204. PubMed ID: 30345551
[No Abstract] [Full Text] [Related]
10. New approved indication for ibrutinib.
Aschenbrenner DS
Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
[No Abstract] [Full Text] [Related]
11. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
12. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
Gaye E; Le Bot A; Talarmin JP; Le Calloch R; Belaz S; Dupont M; Tattevin P
Med Mal Infect; 2018 Jun; 48(4):294-297. PubMed ID: 29402474
[No Abstract] [Full Text] [Related]
13. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
[No Abstract] [Full Text] [Related]
14. Ibrutinib-associated T-cell pseudolymphoma.
Ho AKH; Koh XQ; Liau MMQ; Tan KB; Tan CL
Clin Exp Dermatol; 2019 Oct; 44(7):828-830. PubMed ID: 30623454
[No Abstract] [Full Text] [Related]
15. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
16. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab.
Jin K; Matsuzaki Y; Akasaka E; Nakano H; Sawamura D
J Dermatol; 2019 Mar; 46(3):e108-e109. PubMed ID: 30192400
[No Abstract] [Full Text] [Related]
17. Ibrutinib may impair serological responses to influenza vaccination.
Douglas AP; Trubiano JA; Barr I; Leung V; Slavin MA; Tam CS
Haematologica; 2017 Oct; 102(10):e397-e399. PubMed ID: 28659336
[No Abstract] [Full Text] [Related]
18. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
19. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Sato R; Jacob J; Gaballa S
Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
[No Abstract] [Full Text] [Related]
20. FDA grants accelerated approval for ibrutinib for CLL.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
